Adaptive Biotechnologies

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADPT and other ETFs, options, and stocks.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines.

CEO

Chad Robins

CEOChad Robins

Employees

624

Employees624

Headquarters

Seattle, Washington

HeadquartersSeattle, Washington

Founded

2009

Founded2009

Employees

624

Employees624

ADPT Key Statistics

Market cap

2.76B

Market cap2.76B

Price-Earnings ratio

-52.60

Price-Earnings ratio-52.60

Dividend yield

—

Dividend yield—

Average volume

3.39M

Average volume3.39M

High today

$18.06

High today$18.06

Low today

$15.88

Low today$15.88

Open price

$16.16

Open price$16.16

Volume

6.86M

Volume6.86M

52 Week high

$20.76

52 Week high$20.76

52 Week low

$9.96

52 Week low$9.96

Stock Snapshot

With a market cap of 2.76B, Adaptive Biotechnologies(ADPT) trades at $17.21. The stock has a price-to-earnings ratio of -52.60.

During the trading session on 2026-06-16, Adaptive Biotechnologies(ADPT) shares reached a daily high of $18.06 and a low of $15.88. At a current price of $17.21, the stock is +8.4% higher than the low and still -4.7% under the high.

Trading activity shows a volume of 6.86M, compared to an average daily volume of 3.39M.

Over the past 52 weeks, Adaptive Biotechnologies(ADPT) stock has traded between a high of $20.76 and a low of $9.96.

ADPT News

Benzinga 11h

Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses - Benzinga

...

TipRanks 1d

Adaptive Biotechnologies Plans MRD and Immune Medicine Split

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 1d

Adaptive to plans to separate minimal residual disease, immune medicine segments

Adaptive Biotechnologies (ADPT) announced its intention to pursue a separation of its minimal residual disease and immune medicine businesses. The company is ev...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More ADPT News

The Motley Fool 2d

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?

Francis Lo, Chief People Officer of Adaptive Biotechnologies (ADPT 6.22%), reported the sale of 39,741 shares of Common Stock for a transaction value of approxi...

Nasdaq 5d

Adaptive Biotechnologies Moves 9.7% Higher: Will This Strength Last?

Adaptive Biotechnologies (ADPT) shares rallied 9.7% in the last trading session to close at $18.73. This move can be attributable to notable volume with a highe...

Simply Wall St 7d

Is Adaptive Biotechnologies Turning clonoSEQ’s MRD Momentum Into a Durable Competitive Moat?

In late May 2026, Adaptive Biotechnologies announced that its NGS-based clonoSEQ MRD test was featured in 33 presentations, including a plenary and 14 oral sess...

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.